(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Sutro Biopharma's earnings in 2025 is -$216,767,000.On average, 12 Wall Street analysts forecast STRO's earnings for 2025 to be -$18,344,952, with the lowest STRO earnings forecast at -$18,355,169, and the highest STRO earnings forecast at -$16,805,706. On average, 12 Wall Street analysts forecast STRO's earnings for 2026 to be -$11,232,750, with the lowest STRO earnings forecast at -$16,269,354, and the highest STRO earnings forecast at -$5,363,523.
In 2027, STRO is forecast to generate -$8,770,638 in earnings, with the lowest earnings forecast at -$16,269,354 and the highest earnings forecast at -$357,568.